MedTrace Logo

Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT01978600 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2015-04-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate intraocular pressure (IOP) over a 24-hour period using Simbrinza™ topical ophthalmic suspension.

Conditions

Interventions

DRUG

Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension

Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.

DRUG

Timolol Maleate 0.5%

Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Danyel Carr, MS · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2014-03-31
Completion
2014-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01978600 on ClinicalTrials.gov